Infection and Immunity, November 1998, p. 5301-5306, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Microbiology Department, University of Tennessee, Knoxville, Tennessee 379191 and Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts 021392
Received 17 April 1998/Returned for modification 3 June 1998/Accepted 1 September 1998
| |
ABSTRACT |
|---|
|
|
|---|
The ura-blaster technique for the disruption of Candida albicans genes has been employed in a number of studies to identify possible genes encoding virulence factors of this fungal pathogen. In this study, the URA3-encoded orotidine 5'-monophosphate (OMP) decarboxylase enzyme activities of C. albicans strains with ura-blaster-mediated genetic disruptions were measured. All strains harboring genetic lesions via the ura-blaster construct showed reduced OMP decarboxylase activities compared to that of the wild type when assayed. The activity levels in different gene disruptions varied, suggesting a positional effect on the level of gene expression. Because the URA3 gene of C. albicans has previously been identified as a virulence factor for this microorganism, our results suggest that decreased virulence observed in strains constructed with the ura-blaster cassette cannot accurately be attributed, in all cases, to the targeted genetic disruption. Although revised methods for validating a URA3-disrupted gene as a target for antifungal drug development could be devised, it is clearly desirable to replace URA3 with a different selectable marker that does not influence virulence.
| |
INTRODUCTION |
|---|
|
|
|---|
Fungal species have become an increasingly common cause of human infection, with Candida albicans emerging as the predominant fungal pathogen in both superficial and systemic infections (7). This polymorphic fungus is carried as a commensal by many individuals; however, in patients rendered immunocompromised by circumstances such as AIDS, chemotherapy, and organ transplantation, C. albicans readily becomes pathogenic.
The development of effective strategies for the treatment of C. albicans infections continues to be a major challenge. Effective antifungal agents may prove to be those which target virulence mechanisms important in the pathogenesis of this microorganism. This approach to drug development utilizes molecular biological strategies to identify fungal virulence genes for the determination of targets (23). Unfortunately, induction and analysis of specific genetic lesions required to identify these virulence factors are difficult tasks. Many conventional genetic techniques utilized in the study of bacterial pathogens cannot be applied to C. albicans due to its asexual life cycle and diploid genome (26). Fortunately, proven techniques used with the haploid yeast Saccharomyces cerevisiae are applicable, in certain cases, to the study of C. albicans.
A construct termed the ura-blaster was developed for the disruption of S. cerevisiae genes by Alani et al. (1). It consists of the URA3 gene of S. cerevisiae flanked by direct repeats of a Salmonella hisG sequence and portions of the target gene which can then be used for the disruption of a targeted gene of interest by integrative transformation with URA3 as a selectable marker. Once introduced into the genome, the hisG direct repeats may undergo mitotic recombination to eliminate the URA3 gene, leaving behind a single copy of the hisG repeat sequence at the site of the original integration in the target gene. This disruption technique became attractive in the study of C. albicans because strains could be constructed with targeted disruptions by using the C. albicans URA3 gene as the single selectable marker in a uracil auxotrophic background (ura3/ura3) (8). The final result of the ura-blaster genetic disruption method is an intact copy of the C. albicans URA3 gene located within the ura-blaster cassette at the position in the genome corresponding to one allele of the target gene.
The URA3 gene of C. albicans encodes orotidine 5'-monophosphate (OMP) decarboxylase, the enzyme that catalyzes the conversion of OMP to uridine 5'-monophosphate (UMP), the last step in the de novo pyrimidine biosynthetic pathway. Alterations within this pathway, such as disrupting URA3, result in significant decreases in the in vivo growth rate and pathogenicity of C. albicans (15). Therefore, CAI4, the strain used for the creation of ura-blaster genetic disruptions in C. albicans, is not virulent due to the absence of a functional URA3 gene. Any strain created to test the effect of a gene on virulence must have an intact, functional URA3 gene.
Strains constructed by the ura-blaster disruption technique have the URA3 gene of C. albicans inserted into the targeted gene of interest. These genetically engineered strains are then used to test for altered virulence in a murine model of infection to ascertain whether the targeted gene is a virulence factor. The attenuated virulence frequently observed when investigating these strains is generally attributed to the targeted genetic disruption via the ura-blaster. However, an alteration in URA3 activity within the disruption cassette may also contribute to a decrease in virulence. We undertook the analysis of URA3 gene expression within a variety of strains genetically disrupted by the ura-blaster technique to determine if the ura-blaster mode of disruption alters the activity of the URA3 gene product.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Strains and media. The C. albicans strains utilized in this study and their relevant genotypes are listed in Table 1. Some of these strains were acquired from other investigators including William A. Fonzi, Gerald R. Fink, and Judith Berman. For the maintenance of C. albicans strains, YPD medium (1% yeast extract, 2% Bacto Peptone, 2% dextrose) was used as a complex growth medium. For minimal medium, SD medium (0.67% Difco yeast nitrogen base without amino acids, 2% dextrose) lacking uridine supplementation was used. Two percent agar was added for the solidification of both YPD and SD-ura medium.
|
Materials.
OMP, potassium phosphate (monobasic), and
dithiothreitol (DTT) were obtained from Sigma Chemical Co., St. Louis,
Mo.
-Mercaptoethanol and potassium phosphate (dibasic) were acquired
from Mallinckrodt Speciality Chemicals Co., Paris, Ky. The protein
assay reagent used in determining protein concentrations was acquired
from Bio-Rad Laboratories, Hercules, Calif.
Assay of OMP decarboxylase enzyme activity.
Enzyme activity
was monitored by using a modified version of assays described
previously (22, 30). Cells from a 50-ml culture were
collected at mid-log phase by centrifugation, washed once with 0.1 M
potassium phosphate buffer (pH 7.5) containing 1 mM DTT, and
resuspended to a final volume of 4 ml in the same buffer. The entire
suspension was added to 3 g of glass beads (0.50-mm diameter; B. Braun Biotech International) and vortexed for 2 min at room
temperature. The resulting extract was transferred to a clean tube,
placed on ice, and cleared of particulate matter by centrifugation at
14,000 × g for 20 min at 4°C. The volume of the
final cell lysate, which was stored at
80°C in 30% glycerol for
later use, was approximately 2 ml. Protein concentrations within the
lysates were determined by the method described by Bradford
(4) with bovine serum albumin (BSA) as the standard. The
conversion of OMP to UMP was measured spectrophotometrically at 23°C
by observing the decrease in absorbance of the OMP substrate at 285 nm
for a period of 25 min. The assay mixture in a total volume of 0.5 ml
consisted of the cell lysate (150 µl), 0.1 M potassium phosphate
buffer (pH 6.0), 1.0 µmol of
-mercaptoethanol, and 0.15 µmol of
the OMP substrate. The concentration of OMP in the assay mixture was
calculated by Beer's law with a molar extinction coefficient of
1.65 × 103 cm
1 M
1
(22). A unit of enzyme activity was defined as the quantity of enzyme which catalyzed the conversion of 1 µmol of OMP to UMP per
min. Specific activity was defined as units of enzyme activity per
milligram of protein. Each assay with a particular cell extract was
repeated at least three times, with specific activities reported as
means ± standard deviations of the means.
Growth rate determination. The doubling times of C. albicans strains were calculated in 2× YPD medium and SD-ura medium at 37°C. An overnight culture grown at 37°C was diluted 1 to 500 into 50 ml of either fresh 2× YPD or SD-ura medium. The culture was incubated with shaking at 37°C. The optical density at 600 nm (OD600) of each culture was determined every hour. The doubling times shown in Tables 2 and 3 are the averages of three independent experiments.
| |
RESULTS |
|---|
|
|
|---|
OMP decarboxylase activities of C. albicans
strains.
OMP decarboxylase enzyme activity was first assayed for
control strains SC5314 (Ura+) and CAI4 (Ura
).
SC5314, a clinical isolate, is the parent strain of CAF2-1 and the
grandparent strain of CAI4. SC5314 was used as the relevant wild-type
control in this work, since CAI4 is the beginning strain used in the
construction of the disrupted strains assayed in this study. OMP
decarboxylase assays of SC5314 and CAI4 were performed with three
different cell extracts, each yielding results highly comparable to
each other (Table 2). The enzyme activity
of the C. albicans wild-type strain SC5314 was not
significantly affected by the growth of the culture in SD-ura minimal
medium. The specific activity of OMP decarboxylase was significantly
decreased in the CAI4 strain which contained deletions of both genomic
URA3 copies. There was no detectable conversion of OMP to
UMP when the substrate was incubated in the presence of buffer alone or
with boiled cell extract. The small amount of conversion of OMP to UMP
observed in the CAI4 assays was probably due to enzymes of nucleotide
anabolism other than OMP decarboxylase.
|
ura3/
ura3 strain with one copy of
URA3 reintegrated into the genome, both showed specific
activities comparable to the SC5314-positive control strain.
Assay results of C. albicans strains constructed with ura-blaster-mediated genetic disruptions. Twenty-three constructed C. albicans strains containing one or more genetic disruptions via the ura-blaster construct were assayed for OMP decarboxylase enzyme activity (Table 3). Compared to the wild-type SC5314 strain, the test strains assayed showed 2- to 18-fold less OMP decarboxylase enzyme activity. Repeated assays of various test strains with cell extracts prepared from several independent cultures yielded highly comparable values for specific enzyme activity (data not shown). To examine the possible effect of growth medium on these strains, the enzyme activity of RSM11 grown in SD-ura medium was also determined. YPD or SD-ura growth medium had no apparent effect on the specific activity obtained for test strain RSM11 (Table 3).
|
Growth rate data and germ tube formation of C. albicans strains.
In order to determine whether growth rate
or germ tube formation was affected by the decrease in OMP
decarboxylase enzyme activity within the C. albicans strains constructed with the ura-blaster, the
doubling times in 2× YPD medium and the ability of each strain to form
germ tubes in serum were examined. The doubling times of the control
strains SC5314 (Ura+) and CAI4 (Ura
) did not
vary significantly in 2× YPD medium at the P > 0.10 level (Table 2). In addition, with the exception of strain JKC19, the
doubling times of the constructed strains were not
significantly different from one another (P > 0.03) in 2× YPD and appeared to be somewhat lower in their growth
rates than that of the CAI4 strain from which they were derived. The
doubling times of several strains in SD-ura medium were also determined
(Tables 2 and 3). The doubling times of strains RSM3 and CACB8B-6 were
not statistically different from those of the Ura+ control
strains SC5314 and CAF2-1 at the P > 0.10 level.
However, the doubling times of strains RSM7, RSM17, and CAI4-5, which
all display low levels of OMP decarboxylase enzyme activity, were significantly different from that of the wild-type SC5314 strain.
) formed
germ tubes at rates indistinguishable from one another, indicating that
the level of URA3 gene activity does not directly affect the
ability of cells to form germ tubes (data not shown). With the
exception of strains CAG1, CAG3, CAG4, CAG5, and CAI4-5, the
strains constructed with the ura-blaster were able to form germ
tubes at wild-type levels (data not shown). Strains CAG1, CAG3, CAG4,
CAG5, and CAI4-5 contain disruptions in one or both copies of the
INT1 or RSR1 gene, both of which are involved in germ tube formation (9, 29).
Relationship between OMP decarboxylase activity and virulence of C. albicans strains. Virulence data for 14 of the strains assayed in this study are available (3, 5, 9, 18, 29). To compare results from these previous studies, the day of death of 50% of the mice within a group of immunocompetent mice injected with 106 C. albicans cells via the lateral vein was related to the OMP decarboxylase enzyme activity within the strain (Fig. 1).
|
Relationship between URA3 gene copy number and OMP
decarboxylase specific activity.
Four C. albicans strains assayed in this study
RSM3, CACB8B-6, CACB8B-5,
and CJC01
contain an alternative ura-blaster-mediated disruption in
which one allele contains an additional copy of hisG and
URA3 (see Table 1 for exact genotypes). The existence of
tandem duplications has been noted previously in the process of
disrupting Candida genes via the ura-blaster cassette
(5, 10), possibly due to the formation of a circularized
intermediate form of the linear ura-blaster cassette during
transformation.
cdr1/CDR1 strain with a
hisG-URA3-hisG-URA3-hisG sequence present within the
disrupted gene, did show the highest enzyme activity of any of the
disrupted strains assayed. However, since the three other strains
containing the hisG-URA3-hisG-URA3-hisG sequence did
not have high activities as well, the observed OMP decarboxylase
activity of RSM3 probably cannot be attributed to an extra copy of
URA3 within the disrupted allele.
Relationship between OMP decarboxylase activity and total number of
genetic disruptions.
C. albicans strains with one, two,
or four ura-blaster-mediated genetic disruptions were assayed in this
study (see Table 1 for exact genotypes). The OMP decarboxylase specific
activities of the strains were compared to the numbers of genes
disrupted with the ura-blaster cassette in order to determine if
enzyme activity was affected by the number of times the ura-blaster
cassette was used for disruption. No positive correlation between
OMP decarboxylase specific activities and the numbers of genes
disrupted was observed. Homozygous knockout strains do not, in
general, show less activity than their heterozygous counterparts. For
example, CACB8B-5, a
chs3/
chs3 strain, has an activity
similar to that of CACB8B-6, a
chs3/CHS3 strain. RSM17, a
C. albicans strain in which the ura-blaster cassette
has been used to disrupt two copies of the CDR1 gene and two
copies of the CaMDR1 gene, has a very low OMP decarboxylase
specific activity. However, the low enzyme activity of RSM17 cannot
definitely be attributed to the fact that it contains four
ura-blaster-mediated genetic disruptions.
| |
DISCUSSION |
|---|
|
|
|---|
We have shown that the OMP decarboxylase enzyme activities of
C. albicans strains assayed in this study are
significantly reduced and quite variable compared to the wild-type
enzyme activity observed in Ura+ control strains. In each
of these strains, the ura-blaster cassette, which contains either one
or two tandem copies of the C. albicans URA3 gene,
disrupts the targeted gene of interest in a
ura3/
ura3 background. It is of critical importance that the OMP
decarboxylase enzyme, as encoded by the URA3 gene
within the ura-blaster cassette, retains sufficient activity,
since both uracil auxotrophy and mutations in the pyrimidine
biosynthetic pathway have previously been shown to diminish virulence
in C. albicans (15).
The ura-blaster disruption technique uses URA3, a gene known to affect the virulence of C. albicans, within a hisG-URA3-hisG disruption cassette, in order to identify other genes involved in pathogenesis. Our results indicate that it is necessary to closely examine the OMP decarboxylase activity of a ura-blaster-constructed strain before determining its virulence in order to determine if the gene of interest is actually related to C. albicans pathogenesis. Our results also indicate that the level of URA3 gene activity does not by itself influence the process of germ tube formation. However, reduced enzyme activity contributed to the lower growth rate of some of the tested strains in SD-ura medium. This lower rate of growth in some of the strains due to inadequate OMP decarboxylase activity may cause a decrease in virulence in vivo because a more slowly growing strain can be eliminated by the host's defenses more effectively than a strain which is rapidly reproducing. However, when considering the growth rate data, it is important to note that two strains examined, RSM3 and CACB8B-6, have reduced levels of OMP decarboxylase enzyme activity but are able to grow in SD-ura medium at rates similar to those of the wild-type strain. These results suggest that a wild-type level of enzyme activity is not necessary to maintain a wild-type rate of growth in SD-ura medium.
One strain in this study, JKC19 (
cphI/
cphI), showed
decreased OMP decarboxylase activity but retained wild-type virulence. Since the engineered disruption with the ura-blaster within this strain
does not affect its virulence, it can be concluded that the targeted
gene within JKC19, CPHI, is not a virulence factor. The
reduced OMP decarboxylase activity of JKC19 does not affect its
virulence, implying that C. albicans strains may not
require wild-type enzyme activity to maintain a wild-type level of
virulence. Therefore, some strains with intermediate levels of
enzyme activity are able to maintain wild-type virulence (JKC19) or
wild-type rates of growth in minimal medium (RSM3 and CACB8B-6).
The OMP decarboxylase enzyme levels within these strains may represent a threshold or adequate level of enzyme activity necessary for these
strains to behave like their wild-type parental strains. However, our
results do not accurately define the adequate or sufficient
amount of OMP decarboxylase enzyme activity required by
C. albicans strains.
Strains RSM11 and CACB8B-5, which are both avirulent, have OMP decarboxylase specific activities similar to that of JKC19. Therefore, RSM11 and CACB8B-5 may have sufficient OMP decarboxylase activity, and the avirulence observed is due to the targeted genetic disruptions. RSM17 and CAG3 are avirulent strains which showed very low OMP decarboxylase activities compared to that of the wild type. In this situation, the reason for the apparent lack of virulence is difficult to assign. Avirulence could be the result of decrease in OMP decarboxylase activity, the targeted genetic disruption, or a combination of both factors. The same problem arises with several other strains in the study, such as CAI4-01 and CAG1, which display intermediate virulence in murine models and also have decreased OMP decarboxylase activities. Again, a distinction between the factors which could result in this decreased virulence cannot be determined.
The hisG-URA3-hisG disruption cassettes present within each strain are all derived from the same plasmid (8) and are presumably identical. Therefore, the reduction of OMP decarboxylase activity in the disrupted C. albicans strains is most likely due to altered URA3 expression within the ura-blaster construct. Several phenomena could result in this altered URA3 expression. After insertion into the targeted gene for disruption, the URA3 gene no longer resides at its native locus in the genome. Epigenetic gene regulation or different states of gene expression caused by differential effects of chromosome or chromatin packaging have been observed for many eukaryotes, including fungi (14, 28). An example of this effect is commonly referred to as position effect variegation (11). The S. cerevisiae URA3 gene, which shares 66.8% sequence identity with that of C. albicans (20), is known to be regulated at the level of transcription (2) and is susceptible to positional and orientation effects when manipulated (24). It is possible that the URA3 gene within the ura-blaster construct is not in close proximity to its proper regulatory elements, causing the observed decrease in OMP decarboxylase activity. Positional effects on URA3 expression and regulation may also explain the variability in enzyme activities observed within the constructed C. albicans strains.
The presence of flanking hisG direct repeats within the disruption cassette may also alter the URA3 gene in these constructed C. albicans strains. A proportion of the cells may have lost URA3 due to mitotic recombination between the hisG repeats, resulting in an overall decrease in OMP decarboxylase activity. Repeat-induced mutation (RIP) should also be noted when examining the ura-blaster construct. RIP is a phenomenon observed in some fungal species in which the presence of heterologous flanking repeated sequences increases the frequency of mutation of the gene being flanked (27). It is possible that the URA3 gene within the ura-blaster construct undergoes frequent mutation due to the presence of flanking hisG repeats from Salmonella, resulting in decreased OMP decarboxylase activity. Finally, it has not escaped our attention that the altered expression of URA3, as measured by us in C. albicans cell extracts, may not reflect expression during host infection when many environmental factors may modulate enzyme activity.
Since its application to the study of C. albicans, the ura-blaster technique for sequential gene disruption has been used extensively in searching for genes responsible for the virulence of this fungal pathogen (3, 5, 6, 13, 16, 18, 19, 21, 25, 31). The importance of C. albicans as a significant infectious microorganism in both healthy and immunocompromised individuals warrants the proper identification of genes necessary for its pathogenesis. Our results imply that the decreased in virulence of C. albicans strains constructed with the ura-blaster cassette cannot be definitively attributed, in all cases, to the targeted genetic disruption. The decrease in OMP decarboxylase activities within these strains may contribute to an attenuation in virulence. We conclude that the interpretation of virulence data obtained from this method of genetic disruption must take into account the decreased activity of the URA3 gene product.
There is currently a trend when examining C. albicans strains to reintroduce the wild-type gene back into a strain with both copies of the targeted gene disrupted. One strain employed in this study, CAG5, is representative of this technique. It contains both copies of the INT1 gene disrupted by a hisG sequence with one copy of INT1 and one copy of URA3 reintegrated into the genome. Strain CAG5 displays intermediate virulence and reduced OMP decarboxylase enzyme activity, whereas CAG3, the homozygous disruptant INT1 strain, is avirulent and has reduced enzyme activity. Restoration of one copy of the INT1 gene in CAG5 resulted in a partial recovery of virulence, indicating that INT1 could be a virulence factor. However, the problem of reduced URA3 gene activity still persists. It is possible that full, wild-type virulence was not restored in CAG5 due to inadequate OMP decarboxylase activity.
Alternative methods should most likely be employed in constructing a
C. albicans strain harboring genetic disruptions to
identify possible virulence factors. One revised ura-blaster disruption method would use a stable plasmid to reintroduce the URA3
gene encoding wild-type levels of OMP decarboxylase. Such a method has
been reported elsewhere (17), but plasmid stability may not
be optimized until an authentic C. albicans centromere
is identified and incorporated into a plasmid. Another revised method would reintroduce the URA3 gene into its native locus, where
it should be properly regulated and expressed. Preliminary data
have shown that returning URA3 to its native location in the
genome of a Ura
strain restores both wild-type OMP
decarboxylase enzyme activity and wild-type virulence (data not shown).
However, these additional genetic manipulations have the disadvantage
of introducing mutations complicating the analysis of virulence
studies. Perhaps the most desirable alternative to the
construction of strains for virulence studies would be to use a
selectable marker that encodes an activity not required for virulence
or host survival.
| |
ACKNOWLEDGMENTS |
|---|
We thank the personnel of the Becker laboratory at the University of Tennessee for their support. We are especially grateful to Melinda Hauser for her input in numerous fruitful discussions regarding this project. We also thank Gerald Fink, William Fonzi, and Judith Berman for the strains used in this study.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Microbiology Department, University of Tennessee, F339 Walters Life Sciences Bldg., Knoxville, TN 37996-0845. Phone: (423) 974-3006. Fax: (423) 974-4007. E-mail: jbecker{at}utk.edu.
Editor: T. R. Kozel
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alani, E.,
L. Cao, and N. Kleckner.
1987.
A method for gene disruption that allows for repeated use of URA3 selection in the construction of multiply disrupted yeast strains.
Genetics
116:541-545 |
| 2. | Bach, M., F. Lacroute, and D. Botstein. 1979. Evidence for transcriptional regulation of orotidine-5'-phosphate decarboxylase in yeast by hybridization of mRNA to the yeast structural gene cloned in Escherichia coli. Genetics 76:386-390. |
| 3. | Becker, J. M., L. K. Henry, W. Jiang, and Y. Koltin. 1995. Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infect. Immun. 63:4515-4518[Abstract]. |
| 4. | Bradford, M. M. 1976. A rapid and sensitive assay for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72:248-254[Medline]. |
| 5. |
Bulawa, C. E.,
D. W. Miller,
L. K. Henry, and J. M. Becker.
1995.
Attenuated virulence of chitin-deficient mutants of C. albicans.
Proc. Natl. Acad. Sci. USA
92:10570-10574 |
| 6. | Diez-Orejas, R., G. Molero, F. Navarro-Garcia, J. Pla, C. Nombela, and M. Sanchez-Perez. 1997. Reduced virulence of Candida albicans MKC1 mutants: a role for mitogen-activated protein kinase in pathogenesis. Infect. Immun. 65:833-837[Abstract]. |
| 7. | Edwards, E. J. J. 1990. Candida species, p. 1435-1446. In G. L. Mandell, R. G. Douglas, and J. E. Bennett (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y. |
| 8. | Fonzi, W. A., and M. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728[Abstract]. |
| 9. |
Gale, C. A.,
C. M. Bendel,
M. McClellan,
M. Hauser,
J. M. Becker,
J. Berman, and M. K. Hostetter.
1998.
Linkage of adhesion, filamentous growth and virulence in Candida albicans to a single gene, INT1.
Science
279:1355-1358 |
| 9a. | Gillum, A. M., E. Y. Tsay, and D. R. Kirsch. 1984. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179-182[Medline]. |
| 10. |
Gow, N. A. R.,
P. W. Robbins,
J. W. Lester,
A. J. P. Brown,
W. A. Fonzi,
T. Chapman, and O. S. Kinsman.
1994.
A hyphal-specific chitin synthase gene (CHS2) is not essential for growth, dimorphism or virulence of Candida albicans.
Proc. Natl. Acad. Sci. USA
91:6216-6220 |
| 11. | Hendrich, B. D., and H. F. Willard. 1995. Epigenetic regulation of gene expression: the effect of altered chromatin structure from yeast to mammals. Hum. Mol. Genet. 4:1765-1777[Abstract]. |
| 12. | Ibrahim, A. S., F. Mirbod, S. G. Filler, Y. Banno, G. T. Cole, Y. Kitajima, J. E. Edwards, Y. Nozawa, and M. A. Ghannoum. 1995. Evidence implicating phospholipase as a virulence factor in Candida albicans. Infect. Immun. 63:1993-1998[Abstract]. |
| 13. | Jiang, W., D. Gerhold, E. B. Kmiec, M. Hauser, J. M. Becker, and Y. Koltin. 1997. The topoisomerase I gene from Candida albicans. Microbiology 143:377-386[Abstract]. |
| 14. | Kellum, R., and P. Schedl. 1991. A position-effect assay for boundaries of higher order chromosomal domains. Cell 64:941-950[Medline]. |
| 15. |
Kirsch, D. R., and R. R. Whitney.
1991.
Pathogenicity of Candida albicans auxotrophic mutants in experimental infections.
Infect. Immun.
59:3297-3300 |
| 16. |
Leberer, E.,
D. Harcus,
I. D. Broadbent,
K. L. Clark,
D. Dignard,
K. Ziegelbauer,
A. Schmidt,
N. A. R. Gow,
A. J. P. Brown, and D. Y. Thomas.
1996.
Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus Candida albicans.
Proc. Natl. Acad. Sci. USA
93:13217-13222 |
| 17. | Leberer, E., K. Ziegelbauer, A. Schmidt, D. Harcus, D. Dignard, J. Ash, L. Johnson, and D. Y. Thomas. 1997. Virulence and hyphal formation of Candida albicans require the Ste20p-like protein kinase CaCla4p. Curr. Biol. 7:539-546[Medline]. |
| 18. |
Liu, H.,
J. Köhler, and G. R. Fink.
1994.
Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog.
Science
266:1723-1726 |
| 19. | Lo, H., J. Köhler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-949[Medline]. |
| 20. | Losberger, C., and J. F. Ernst. 1989. Sequence and transcript analysis of the C. albicans URA3 gene encoding orotidine-5'-phosphate decarboxylase. Curr. Genet. 16:153-157[Medline]. |
| 21. |
Mio, T.,
T. Yabe,
M. Sudoh,
Y. Satoh,
T. Nakajima,
M. Arisawa, and H. Yamada-Okabe.
1996.
Role of three chitin synthase genes in the growth of Candida albicans.
J. Bacteriol.
178:2416-2419 |
| 22. | Myers, K. M., P. S. Sypherd, and W. A. Fonzi. 1995. Use of URA3 as a reporter of gene expression in C. albicans. Curr. Genet. 27:243-248[Medline]. |
| 23. | Perfect, J. R. 1996. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob. Agent. Chemother. 40:1577-1583[Abstract]. |
| 24. | Rose, M., P. Grisafi, and D. Botstein. 1984. Structure and function of the yeast URA3 gene: expression in Escherichia coli. Gene 29:113-124[Medline]. |
| 25. |
Sarthy, A. V.,
T. McGonigal,
M. Coen,
D. J. Frost,
J. A. Meulbroek, and R. C. Goldman.
1997.
Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3- -glucosyltransferase.
Microbiology
143:367-376[Abstract].
|
| 26. | Scherer, S., and P. T. Magee. 1991. Genetics of Candida albicans. Microbiol. Rev. 54:226-241. |
| 27. | Selker, E. 1990. Premeiotic instability of repeated sequences in Neurospora crassa. Annu. Rev. Genet. 24:579-613[Medline]. |
| 28. | Tartof, K. D. 1994. Position effect variegation in yeast. Bioessays 16:713-714[Medline]. |
| 29. | Yaar, L., M. Mevarech, and Y. Koltin. 1997. A Candida albicans RAS-related gene (CaRSR1) is involved in budding, cell morphogenesis and hypha development. Microbiology 143:3033-3044[Abstract]. |
| 30. | Yoshimoto, A., K. Umezu, K. Kobayashi, and K. Tomita. 1978. Orotidylate decarboxylase (yeast). Methods Enzymol. 54:74-79. |
| 31. | Zhao, X., G. E. McElhaney-Feser, M. J. Sheridan, S. E. Broedel, and R. L. Cihlar. 1997. Avirulence of Candida albicans FAS2 mutants in a mouse model of systemic candidiasis. Infect. Immun. 65:829-832[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|